STOCK TITAN

Windward Bio: Omega funds buy 1.75M shares at $17

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Windward Bio Group AG director Otello Stampacchia reported transactions involving Omega Fund VII, L.P. and Omega Fund VIII, L.P.: each fund purchased 875,000 common shares at $17.00 per share on November 16, 2026. The funds’ Series A and Series B preferred shares converted automatically into 3,588,520 common shares on a 1-to-1 basis immediately before the initial public offering closed. The preferred shares had no expiration date.

Insider Stampacchia Otello
Role Director
Bought 1,750,000 shs ($29.75M)
Type Security Shares Price Value
Conversion Series A Preferred Shares F3, F1 1,262,628 $0.00 $0.00
Conversion Series A Preferred Shares F3, F2 1,262,626 $0.00 $0.00
Conversion Series B Preferred Shares F3, F1 531,632 $0.00 $0.00
Conversion Series B Preferred Shares F3, F2 531,634 $0.00 $0.00
Purchase Common Shares F1 875,000 $17.00 $14.88M
Purchase Common Shares F2 875,000 $17.00 $14.88M
Conversion Common Shares F3, F1 1,262,628 -- --
Conversion Common Shares F3, F2 1,262,626 -- --
Conversion Common Shares F3, F1 531,632 -- --
Conversion Common Shares F3, F2 531,634 -- --
Holdings After Transaction: Series A Preferred Shares — 0 shares (Indirect, By Omega Fund VII, L.P.); Series A Preferred Shares — 0 shares (Indirect, By Omega Fund VIII, L.P.); Series B Preferred Shares — 0 shares (Indirect, By Omega Fund VII, L.P.); Series B Preferred Shares — 0 shares (Indirect, By Omega Fund VIII, L.P.); Common Shares — 2,669,260 shares (Indirect, By Omega Fund VII, L.P.); Common Shares — 2,669,260 shares (Indirect, By Omega Fund VIII, L.P.)
Holdings Before and After: Series A Preferred Shares, 1,262,628 to 0 shares (Indirect, By Omega Fund VII, L.P.); Series A Preferred Shares, 1,262,626 to 0 shares (Indirect, By Omega Fund VIII, L.P.); Series B Preferred Shares, 531,632 to 0 shares (Indirect, By Omega Fund VII, L.P.); Series B Preferred Shares, 531,634 to 0 shares (Indirect, By Omega Fund VIII, L.P.); Common Shares, 0 to 2,669,260 shares (Indirect, By Omega Fund VII, L.P.); Common Shares, 0 to 2,669,260 shares (Indirect, By Omega Fund VIII, L.P.)
Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (3)
  1. F1. Shares held directly by Omega Fund VII, L.P. ("Omega VII"). Omega Fund VII GP, L.P. ("Omega VII GP") is the sole general partner of Omega VII. Omega Fund VII GP Manager, Ltd. ("Omega VII Manager") is the sole general partner of Omega VII GP. The Reporting Person, Claudio Nessi and Francesco Draetta are the directors of Omega VII Manager and each disclaims beneficial ownership of the shares held by Omega VII except to the extent of his pecuniary interest therein, if any.
  2. F2. Shares held directly by Omega Fund VIII, L.P. ("Omega VIII"). Omega Fund VIII GP, L.P. ("Omega VIII GP") is the sole general partner of Omega VIII. Omega Fund VIII GP Manager, Ltd. ("Omega VIII Manager") is the sole general partner of Omega VIII GP. The Reporting Person, Claudio Nessi and Francesco Draetta are the directors of Omega VIII Manager and each disclaims beneficial ownership of the shares held by Omega VIII except to the extent of his pecuniary interest therein, if any.
  3. F3. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1 to 1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
Common shares purchased 1,750,000 shares Omega Fund VII and Omega Fund VIII purchased 875,000 shares each on November 16, 2026.
Purchase price $17.00 per share Common-share purchases by Omega Fund VII and Omega Fund VIII on November 16, 2026.
Common shares received on conversion 3,588,520 shares Series A and Series B preferred shares converted automatically on a 1-to-1 basis immediately before the initial public offering closed.
Series A Preferred Shares financial
"the automatic conversion of Series A Preferred Shares before the IPO closing"
Series A preferred shares are an early-stage class of ownership sold to investors that gives them special protections and payment priority over regular common stock. Think of them as a safer seat on a bus: if the company earns money or is sold, holders get paid before ordinary shareholders, and they often can convert to common shares later to share upside; that mix of safety and growth potential helps investors manage risk and reward.
Series B Preferred Shares financial
"the automatic conversion of Series B Preferred Shares before the IPO closing"
Series B preferred shares are a class of company stock issued during a later round of private financing that gives investors priority over common shareholders for payouts and protections if the company is sold or liquidated. Think of them as a VIP ticket that often includes a fixed claim on returns, possible regular payments, and the option to convert into regular shares; that mix of safety and upside helps investors assess risk and potential reward.
initial public offering financial
"immediately prior to the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many WWB common shares did Omega Fund VII and Omega Fund VIII purchase?

Each fund purchased 875,000 common shares at $17.00 per share on November 16, 2026.

How did the preferred shares held by the Omega funds convert?

They converted automatically on a 1-to-1 basis into common shares immediately before the initial public offering closed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stampacchia Otello

(Last)(First)(Middle)
C/O WINDWARD BIO GROUP AG
AESCHENPLATZ 6

(Street)
BASEL4052

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
WINDWARD BIO GROUP AG [ WWB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/16/2026P875,000A$17875,000IBy Omega Fund VII, L.P.(1)
Common Shares11/16/2026P875,000A$17875,000IBy Omega Fund VIII, L.P.(2)
Common Shares11/16/2026C1,262,628A(3)2,137,628IBy Omega Fund VII, L.P.(1)
Common Shares11/16/2026C1,262,626A(3)2,137,626IBy Omega Fund VIII, L.P.(2)
Common Shares11/16/2026C531,632A(3)2,669,260IBy Omega Fund VII, L.P.(1)
Common Shares11/16/2026C531,634A(3)2,669,260IBy Omega Fund VIII, L.P.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Preferred Shares(3)11/16/2026C1,262,628 (3) (3)Common Shares1,262,628$00IBy Omega Fund VII, L.P.(1)
Series A Preferred Shares(3)11/16/2026C1,262,626 (3) (3)Common Shares1,262,626$00IBy Omega Fund VIII, L.P.(2)
Series B Preferred Shares(3)11/16/2026C531,632 (3) (3)Common Shares531,632$00IBy Omega Fund VII, L.P.(1)
Series B Preferred Shares(3)11/16/2026C531,634 (3) (3)Common Shares531,634$00IBy Omega Fund VIII, L.P.(2)
Explanation of Responses:
1. Shares held directly by Omega Fund VII, L.P. ("Omega VII"). Omega Fund VII GP, L.P. ("Omega VII GP") is the sole general partner of Omega VII. Omega Fund VII GP Manager, Ltd. ("Omega VII Manager") is the sole general partner of Omega VII GP. The Reporting Person, Claudio Nessi and Francesco Draetta are the directors of Omega VII Manager and each disclaims beneficial ownership of the shares held by Omega VII except to the extent of his pecuniary interest therein, if any.
2. Shares held directly by Omega Fund VIII, L.P. ("Omega VIII"). Omega Fund VIII GP, L.P. ("Omega VIII GP") is the sole general partner of Omega VIII. Omega Fund VIII GP Manager, Ltd. ("Omega VIII Manager") is the sole general partner of Omega VIII GP. The Reporting Person, Claudio Nessi and Francesco Draetta are the directors of Omega VIII Manager and each disclaims beneficial ownership of the shares held by Omega VIII except to the extent of his pecuniary interest therein, if any.
3. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1 to 1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
/s/ Scott Applebaum, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading